NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla
Executive Summary
After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.